Sir, In the last year, it has become evident that the plasmid-located colistin resistance gene mcr-1 has a worldwide distribution. 1 Colistin is widely used in veterinary medicine, particularly in pigs and poultry, and the selection pressure in livestock production is a likely driver of the persistence and dissemination of mcr-1.
2 It is not surprising that a large proportion of mcr-1-positive isolates described thus far originate from food-producing animal reservoirs. 1 However, plasmid-mediated colistin resistance is also reported from diseased and healthy humans. This is concerning, as colistin is particularly important as one of the last therapeutic options for human infections caused by multiresistant bacteria. Furthermore, plasmid-mediated colistin resistance has been documented for other animal categories such as companion animals, reptiles and birds as well as in environmental samples of sewage, water and vegetables. 1 In Europe, sales of veterinary medicinal products, including the polymyxin colistin, are documented through the European Surveillance of Veterinary Antimicrobial Consumption reports, and wide variations are observed between countries. 3 In Norway, the sale of polymyxin veterinary medicinal products was zero during the years 2010-15. Historical data also show that there has been no sale of polymyxins for use in animals during the years 1993-2009 in Norway (http://www.vetinst.no/overvaking/antibioti karesistens-norm-vet). Retrospective molecular screening of Enterobacteriaceae exhibiting colistin MICs above the breakpoint recommended by EUCAST (.2 mg/L), has demonstrated absence of mcr-1-positive isolates in samples from animals, food and feed originating from Norway for the years 2010-15. 4 However, in 2016 the monitoring programme NORM-VET included samples of imported seafood and imported raw dog food. From two samples, one of each category, mcr-1-positive Escherichia coli were detected. The seafood sample was imported scampi from Bangladesh. The frozen dog food sample originated from the UK and contained turkey meat, fruit and vegetables. These samples were screened selectively for quinolone-resistant E. coli (QREC). Presumptive QREC were susceptibility tested using broth microdilution (Sensititre V R ; TREK Diagnostic Systems Ltd, Thermo Scientific, Waltham, MA, USA). The two isolates had colistin MICs of 4 mg/L and were subjected to further investigations. WGS was performed using a MiSeq platform. Data were analysed using online tools available from the Center for Genomic Epidemiology (http://www. genomicepidemiology.org) or manually by search via CLC Main Workbench (CLC bio; QIAGEN, Aarhus, Denmark). WGS data documented mcr-1 in both isolates and the multilocus STs 3014 and 48. In the scampi isolate, a 132 kb contig contained both mcr-1 and the IncHI2 replicon marker, indicating that mcr-1 was located on this plasmid. Both isolates contained genes encoding resistance to several classes of antimicrobial agents (Table 1) . Furthermore, a gene responsible for quaternary ammonium compound resistance (qacH) and tellurite resistance operons were present in both isolates. The dog food isolate also contained genes encoding mercury resistance. Conjugation experiments were performed in triplicate, but no transconjugants containing mcr-1 were obtained.
Only one finding of plasmid-mediated colistin resistance has been reported in humans in Norway. This was an E. coli with mcr-1 from a traveller returning from India with enteritis. 4 Human travellers have probably contributed to the worldwide spread of antimicrobial resistance. However, international trade in live animals, animal products, feed and food may represent an important route of dissemination, enabling the global spread of important resistance types and their introduction into geographic areas where they may be rare or absent. Humans may acquire antimicrobialresistant bacteria through handling or consumption of contaminated food. Likewise, companion animals may acquire resistant bacteria via their feed. Sharing of common Enterobacteriaceae clones among family members and their dogs has been described, 5 including mcr-1-positive E. coli, 6 emphasizing the possibility of zoonotic transmission.
Interestingly, we found mcr-1-positive isolates via screening for QREC. European studies have described that turkeys and broilers are associated with the highest prevalence of mcr-1.
7,8 According to European surveillance data these animal species are also associated with high occurrences of QREC.
9 So far, most detections of mcr-1 have been a result of retrospective screening of historical strain collections or WGS databases, whereas fewer reports have dealt with detection in 'real time'. Our findings show the importance of risk-based screening of relevant samples to uncover possible sources of bacteria resistant to last-resort antimicrobials. Food products imported from areas with a high environmental load of resistant bacteria and with higher usage of antimicrobials should receive special attention. This is exemplified by the findings in the present study, but also by findings from Switzerland where mcr-1-positive E. coli in vegetables imported from Thailand and Vietnam have been reported. 10 Furthermore, a study performed in Canada found carbapenem-resistant bacteria in samples of imported seafood from Asia.
11
Our data represent single findings from two categories of imported food and feedstuff. More comprehensive monitoring to follow up these reservoirs is required. Furthermore, there is a need to extend our knowledge regarding how to perform a future riskbased sampling for antimicrobial resistance in 'low prevalence' settings to achieve maximum sensitivity for the detection of rare, but highly important mechanisms of resistance. Sir, Linezolid, an oxazolidinone with broad-spectrum activity against Gram-positive bacteria, is an effective antibiotic against Staphylococcus aureus and MRSA infection. However, there is limited information on its use in breastfeeding women and the potential for subsequent absorption in the nursing infant, which makes provision of advice to the mother difficult and may lead to parental anxiety. To date, there has been only one case report 1 and one study, 2 both showing linezolid to be detectable in expressed breast milk, but no report of drug levels in nursing infants. The product literature states that linezolid is excreted in the milk of lactating rodents at a similar concentration to that of maternal plasma. 3 Since the absolute bioavailability of linezolid approaches 100%, 3 if the amount of linezolid excreted in human breast milk is sufficiently high, it may be theoretically possible for the drug to be found in clinically significant amounts in the systemic circulation of the infant.
We present a case report of a nursing mother treated with linezolid for S. aureus bacteraemia. Linezolid was prescribed because of a proven b-lactam allergy and no intravenous access. We measured linezolid levels in expressed breast milk provided by the patient and in one serum sample from the exclusively breastfed newborn infant.
Expressed breast milk was collected at various times over a 24 h period by the patient. Collection commenced 45 h after treatment with 600 mg of oral linezolid every 12 h was started. The infant required therapeutic drug monitoring for another antibiotic and the residual serum from this sample was used to measure linezolid levels. Linezolid levels were measured in all samples using HPLC by the Antimicrobial Reference Laboratory in Southmead Hospital, Bristol, UK, using a validated method. 4 The levels obtained for breast milk ranged from 3.5 to 12.2 mg/L with an average level of 8.1 mg/L. Serum measurement of linezolid in the newborn infant was ,0.2 mg/L. A breast milk sample obtained 1 h after the infant's serum sample and 4 h after linezolid administration measured 8.9 mg/L (Figure 1) .
The recommended treatment dose of linezolid for neonates is 10 mg/kg every 8-12 h. Assuming breast milk intake of 750 mL per day, 5 based on our findings the average daily exposure of the nursing infant to linezolid was estimated to be 6 mg, which is ,9% of the daily treatment dose in an average 3.5 kg neonate. This is consistent with the currently available literature suggesting that the nursing infant of a breastfeeding mother on standard-dose linezolid therapy would receive around 3%-6% of the normal infant treatment dose of linezolid.
1 Interestingly, the infant linezolid serum concentration measured 44 h after commencement of maternal oral linezolid administration was below the limit of HPLC detection despite the infant being fed exclusively on breast milk. Unfortunately, it was not possible to ascertain the timing of the serum sample in relation to when the infant was last fed, but the breast milk sample collected closest in time to the serum sampling had a concentration of 8.9 mg/L.
To our knowledge, this is the first report describing the measurement of linezolid in both the breast milk of the mother and in the serum of the nursing infant. We conclude that, both from our results and a theoretical consideration, the risk of systemic exposure of the infant to linezolid during breastfeeding by mothers receiving the drug is low. However, until further data are available to confirm the safety of incidental exposure of the infant to linezolid in breast milk, it would be prudent to continue to monitor for any side effects possibly relating to linezolid exposure, such as diarrhoea and bone marrow suppression. 
